RU2007135339A - Производные пиридилуксусной кислоты - Google Patents

Производные пиридилуксусной кислоты Download PDF

Info

Publication number
RU2007135339A
RU2007135339A RU2007135339/04A RU2007135339A RU2007135339A RU 2007135339 A RU2007135339 A RU 2007135339A RU 2007135339/04 A RU2007135339/04 A RU 2007135339/04A RU 2007135339 A RU2007135339 A RU 2007135339A RU 2007135339 A RU2007135339 A RU 2007135339A
Authority
RU
Russia
Prior art keywords
optionally substituted
alkyl group
prodrug
compound according
group
Prior art date
Application number
RU2007135339/04A
Other languages
English (en)
Inventor
Хиронобу МАЕЗАКИ (JP)
Хиронобу Маезаки
Нобухиро СУЗУКИ (JP)
Нобухиро СУЗУКИ
Original Assignee
Такеда Фармасьютикал Компани Лимитед (Jp)
Такеда Фармасьютикал Компани Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36370977&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2007135339(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Такеда Фармасьютикал Компани Лимитед (Jp), Такеда Фармасьютикал Компани Лимитед filed Critical Такеда Фармасьютикал Компани Лимитед (Jp)
Publication of RU2007135339A publication Critical patent/RU2007135339A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/55—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Claims (15)

1. Соединение, представленное формулой (I):
Figure 00000001
где R1 представляет собой С1-6-алкильную группу, необязательно замещенную С3-10-циклоалкильной группой,
R2 представляет собой С2-6-алкильную группу,
R3 представляет собой атом водорода, С1-6-алкильную группу или атом галогена и
X представляет собой -OR6 или -NR4R5,
где R4 и R6 - каждый независимо представляет собой атом водорода, необязательно замещенную углеводородную группу или необязательно замещенную гетероциклическую группу, R5 представляет собой необязательно замещенную углеводородную группу, необязательно замещенную гетероциклическую группу или необязательно замещенную гидроксигруппу, или R4 и R5 необязательно образуют совместно со смежным атомом азота необязательно замещенный азотсодержащий гетероцикл,
или его соль.
2. Соединение по п.1, в котором X представляет собой -OH.
3. Соединение по п.1, в котором R1 представляет собой С3-6-алкильную группу.
4. Соединение по п.1, в котором R3 представляет собой С1-6-алкильную группу.
5. Соединение по п.1, которое представляет собой
[5-(аминометил)-2-этил-6-изобутил-4-(4-метилфенил)пиридин-3-ил]уксусную кислоту;
[5-(аминометил)-2,6-диизобутил-4-(4-метилфенил)пиридин-3-ил]уксусную кислоту;
[5-(аминометил)-2-этил-4-(4-метилфенил)-6-неопентилпиридин-3-ил]уксусную кислоту; или
1-{[5-(аминометил)-2-этил-4-(4-метилфенил)-6-неопентилпиридин-3-ил]ацетил}-L-пролинамид;
или его соль.
6. Пролекарство соединения по п.1.
7. Фармацевтическое средство, содержащее соединение по п.1 или его пролекарство.
8. Фармацевтическое средство по п.7, которое представляет собой средство для профилактики или лечения диабета, диабетических осложнений, нарушения толерантности к глюкозе или ожирения.
9. Ингибитор пептидазы, содержащий соединение по п.1 или его пролекарство.
10. Ингибитор по п.9, в котором пептидаза представляет собой дипептидилпептидазу-IV.
11. Применение соединения по п.1 или его пролекарства для получения средства для профилактики или лечения диабета, диабетических осложнений, нарушения толерантности к глюкозе или ожирения.
12. Применение соединения по п.1 или его пролекарства для получения ингибитора пептидазы.
13. Способ предотвращения или лечения диабета, диабетических осложнений, нарушения толерантности к глюкозе или ожирения у млекопитающих, который включает введение соединения по п.1 или его пролекарства указанному млекопитающему.
14. Способ ингибирования пептидазы у млекопитающих, который включает введение соединения по п.1 или его пролекарства указанному млекопитающему.
15. Способ получения соединения, представленного формулой (I-a):
Figure 00000002
где R1 представляет собой С1-6-алкильную группу, необязательно замещенную С3-10-циклоалкильной группой,
R2 представляет собой С2-6-алкильную группу и
R3 представляет собой атом водорода, С1-6-алкильную группу или атом галогена или его соль, включающий проведение гидролиза и снятия защитной группы соединения, представленного формулой (1):
Figure 00000003
где P представляет собой атом водорода или аминозащитную группу, и R1, R2 и R3 - каждый представляет собой заместитель, как определено выше, или его соль.
RU2007135339/04A 2005-02-25 2006-02-24 Производные пиридилуксусной кислоты RU2007135339A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2005-052018 2005-02-25
JP2005052018 2005-02-25

Publications (1)

Publication Number Publication Date
RU2007135339A true RU2007135339A (ru) 2009-03-27

Family

ID=36370977

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2007135339/04A RU2007135339A (ru) 2005-02-25 2006-02-24 Производные пиридилуксусной кислоты

Country Status (17)

Country Link
US (1) US20090088419A1 (ru)
EP (1) EP1851202A1 (ru)
KR (1) KR20070106794A (ru)
CN (1) CN101166725A (ru)
AR (1) AR055563A1 (ru)
AU (1) AU2006217677A1 (ru)
BR (1) BRPI0607433A2 (ru)
CA (1) CA2598934A1 (ru)
CR (1) CR9369A (ru)
IL (1) IL185399A0 (ru)
MA (1) MA29323B1 (ru)
NO (1) NO20074668L (ru)
PE (1) PE20061099A1 (ru)
RU (1) RU2007135339A (ru)
TW (1) TW200640862A (ru)
WO (1) WO2006090915A1 (ru)
ZA (1) ZA200708144B (ru)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEP20115359B (en) 2006-06-27 2011-12-26 Takeda Pharmaceutical Fused cyclic compounds
WO2008017381A1 (de) 2006-08-08 2008-02-14 Sanofi-Aventis Arylaminoaryl-alkyl-substituierte imidazolidin-2,4-dione, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und ihre verwendung
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
AR072707A1 (es) 2008-07-09 2010-09-15 Sanofi Aventis Compuestos heterociclicos, procesos para su preparacion, medicamentos que comprenden estos compuestos y el uso de los mismos
GB2463788B (en) 2008-09-29 2010-12-15 Amira Pharmaceuticals Inc Heteroaryl antagonists of prostaglandin D2 receptors
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
WO2011023754A1 (en) 2009-08-26 2011-03-03 Sanofi-Aventis Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
EP2308847B1 (en) 2009-10-09 2014-04-02 EMC microcollections GmbH Substituted pyridines as inhibitors of dipeptidyl peptidase IV and their application for the treatment of diabetes and related diseases
EP2521721B1 (en) 2009-12-30 2014-10-01 Shanghai Fochon Pharmaceutical Co. Ltd 3-(3-aminopiperidin-1-yl)-5-oxo-1,2,4-triazine derivates as dipeptidyl peptidase iv(dpp-iv) inhibitors
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8901114B2 (en) 2011-03-08 2014-12-02 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
IN2015DN03795A (ru) 2012-10-24 2015-10-02 Inserm Inst Nat De La Santé Et De La Rech Médicale
US10426818B2 (en) 2015-03-24 2019-10-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Method and pharmaceutical composition for use in the treatment of diabetes
CN109305957B (zh) * 2017-07-26 2021-08-03 上海医药工业研究院 苯基吡啶类化合物及其在dpp-4酶抑制剂的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0648212B1 (en) * 1992-07-03 2001-10-24 Smithkline Beecham Plc Benzoxazole and benzothiazole derivatives as pharmaceutical
US5827865A (en) * 1995-03-09 1998-10-27 Smithkline Beecham P.L.C. Heterocyclic compounds as pharmaceutical
US6291495B1 (en) * 1997-02-24 2001-09-18 Robert B. Rieveley Method and composition for the treatment of diabetes
US6153632A (en) * 1997-02-24 2000-11-28 Rieveley; Robert B. Method and composition for the treatment of diabetes
EP1218336A2 (en) * 1999-09-20 2002-07-03 Takeda Chemical Industries, Ltd. Melanin concentrating hormone antagonist
CA2474578C (en) * 2002-02-13 2009-08-25 F. Hoffmann-La Roche Ag Novel pyridin- and pyrimidin-derivatives
WO2004014860A2 (en) * 2002-08-08 2004-02-19 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds as peptidase inhibitors
ATE517887T1 (de) * 2003-02-13 2011-08-15 Msd Kk Neue 2-pyridincarbonsäureamidderivate
TW200523252A (en) * 2003-10-31 2005-07-16 Takeda Pharmaceutical Pyridine compounds
EP2314576A1 (en) * 2003-11-05 2011-04-27 F.Hoffmann-La Roche Ag Phenyl derivatives as PPAR agonists
JP2007509996A (ja) * 2003-11-05 2007-04-19 エフ．ホフマン−ラ　ロシュ　アーゲー Ｐｐａｒ活性化剤としてのヘテロアリール誘導体

Also Published As

Publication number Publication date
CN101166725A (zh) 2008-04-23
EP1851202A1 (en) 2007-11-07
PE20061099A1 (es) 2006-12-05
CA2598934A1 (en) 2006-08-31
NO20074668L (no) 2007-11-15
CR9369A (es) 2007-10-22
AU2006217677A1 (en) 2006-08-31
IL185399A0 (en) 2008-02-09
WO2006090915A1 (en) 2006-08-31
TW200640862A (en) 2006-12-01
US20090088419A1 (en) 2009-04-02
KR20070106794A (ko) 2007-11-05
AR055563A1 (es) 2007-08-22
ZA200708144B (en) 2008-11-26
BRPI0607433A2 (pt) 2009-09-08
MA29323B1 (fr) 2008-03-03

Similar Documents

Publication Publication Date Title
RU2007135339A (ru) Производные пиридилуксусной кислоты
WO2007125405A3 (en) Substituted 2-amino-fused heterocyclic compounds
RU2007101653A (ru) Производные 1-азабицикло[3.3.1]нонанов
TW200833663A (en) Therapeutic agents
RU2005114021A (ru) Производные имидазола и их применение в качестве периферически-селективных ингибиторов дофамин-бета-гидролазы
MY148566A (en) Crystalline solvates and complexes of (is) -1, 5- anhydro-1 -c-(3-( (phenyl) methyl) phenyl) -d-glucitol derivatives with amino acids as sglt2 inhibitors for the treatment of diabetes
EP2371811A3 (en) Azetidinecarboxylic acid derivative and medicinal use thereof
RU2010143817A (ru) Лекарственное средство, включающее совместное применение или комбинацию ингибитора dpp-iv и другого лекарственного средства для лечения диабета
RU2010126056A (ru) Органические соединения
TW200505919A (en) DPP-IV inhibitors
NO20055680L (no) Heksahydropyridoisokinoliner som DPP-IV-inhibitorer
WO2005075425A3 (en) Substituted bisarylurea derivatives as kinase inhibitors
CA2592345A1 (en) Piperidine and azetidine derivatives as glyt1 inhibitors
WO2009063202A3 (en) Use of crth2 antagonist compounds
WO2004037181A3 (en) Glycinenitrile-based inhibitors of dipeptidyl peptidase iv and methods
CA2565813A1 (en) Substituted methyl aryl or heteroaryl amide compounds
ATE427926T1 (de) Cycloalkylaminderivate
ECSP066653A (es) Derivados de bencenosulfonilamino-piridin-2-il y compuestos relacionados como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa tipo 1(ii-beta-hsd-1) para el tratamiento de la diabetes y de la obesidad
RU2009126767A (ru) Производное 1-фенил-1-тио-d-глюцитола
WO2006058628A3 (en) Substituted benzoquinolizines as dpp-iv inhibitors for the treatment of diabetes
JP2004315496A5 (ru)
NO20070088L (no) 1-, (3R)-amino-4-(2-fluor-fenyl)-butyl !-pyrrolidin-(2R)-karboksylsyre-benzyl amin derivater og beslektede forbindelser som dipeptidyl-peptidase IV (DPP??IV) inhibitorer for behandling av type 2
WO2010095768A8 (en) 4 -isopropylphenyl glucitol compounds as sglt1 inhibitors
WO2007024843A3 (en) Pyrimidinyl-pyrazole inhibitors of aurora kinases
TNSN07419A1 (en) Methods for treating drug resistant cancer

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20100504